We are live on ! Find out more
FA

Forefront Analytics Portfolio holdings

AUM $92M
1-Year Est. Return 25.18%
This Fund
S&P 500
This Quarter Est. Return
+8.08%
1 Year Est. Return
+25.18%
3 Year Est. Return
+50.89%
5 Year Est. Return
+36.12%
10 Year Est. Return
AUM
$203M
AUM Growth
+$26.2M
Cap. Flow
+$11.7M
Cap. Flow %
5.76%
Top 10 Hldgs %
54.44%
Holding
71
New
4
Increased
40
Reduced
21
Closed
4

Sector Composition

Rank Sector Weight
1 Miscellaneous 97.72%
2 Healthcare 1.34%
3 Technology 0.42%
4 Financials 0.29%
5 Industrials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INCY icon
51
Incyte
INCY
$25.8B
$293K 0.14%
4,668
+1,130
+32% +$63.9K
UNH icon
52
UnitedHealth
UNH
$355B
$286K 0.14%
539
-3
-0.6% -$1.6K
REGN icon
53
Regeneron Pharmaceuticals
REGN
$85.3B
$280K 0.14%
319
+26
+9% +$21.4K
TMO icon
54
Thermo Fisher Scientific
TMO
$226B
$233K 0.11%
+437
New +$212K
MDT icon
55
Medtronic
MDT
$121B
$201K 0.1%
+2,436
New +$186K
FUSN
56
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$161K 0.08%
16,715
-16,970
-50% -$82.5K
ANNX icon
57
Annexon
ANNX
$918M
$142K 0.07%
31,280
-400
-1% -$990
NKTX icon
58
Nkarta
NKTX
$206M
$137K 0.07%
20,767
-18,890
-48% -$48.9K
COGT icon
59
Cogent Biosciences
COGT
$6.03B
$117K 0.06%
+19,982
New +$153K
ZURA icon
60
Zura Bio
ZURA
$593M
$99.1K 0.05%
21,229
+6,765
+47% +$33.8K
PSTX
61
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$85.6K 0.04%
25,469
+500
+2% +$1.29K
MREO
62
Mereo BioPharma
MREO
$41.6M
$83.4K 0.04%
36,124
-29,525
-45% -$56.5K
LONA
63
LeonaBio Inc
LONA
$72.1M
$72.3K 0.04%
2,977
+896
+43% +$15.9K
ACHL
64
DELISTED
Achilles Therapeutics
ACHL
$67.8K 0.03%
76,269
-1,900
-2% -$1.63K
KRON
65
DELISTED
Kronos Bio
KRON
$61.5K 0.03%
49,168
+9,200
+23% +$10.2K
GERN icon
66
Geron
GERN
$989M
$59.7K 0.03%
28,316
-800
-3% -$1.56K
CTMX icon
67
CytomX Therapeutics
CTMX
$806M
$47.8K 0.02%
30,846
-18,575
-38% -$24.4K
ALXO icon
68
ALX Oncology
ALXO
$279M
-13,769
Closed -$66.1K
JSPR icon
69
Jasper Therapeutics
JSPR
$23M
-11,079
Closed -$77.6K
THRX
70
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
-17,672
Closed -$47.5K
ORTX
71
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
-14,183
Closed -$110K

Similar funds

Forefront Analytics's Q4 2023 Portfolio in Review

As of Q4 2023, Forefront Analytics held 71 positions worth $203M, up 15% from $176M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Forefront Analytics deployed $11.7M of net new capital in Q4 2023, opening 4 new positions and adding to 40 existing holdings. Its largest new stake was Northern Trust STOXX US ESG Select ETF: 39,972 shares worth $4.64M.

By sector, the portfolio is most concentrated in Miscellaneous at 98% of assets, down from 98% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was iShares MSCI USA Momentum Factor ETF, an estimated $7.12M trimmed.

  • Forefront Analytics's largest Q4 2023 buy was Northern Trust STOXX US ESG Select ETF: 39,972 shares worth $4.64M.
  • Forefront Analytics added most to Vanguard Total International Bond ETF in Q4 2023, an estimated $8.27M increase.
  • Forefront Analytics's biggest Q4 2023 reduction was iShares MSCI USA Momentum Factor ETF, cutting an estimated $7.12M.
  • Forefront Analytics fully exited Orchard Therapeutics plc American Depositary Shares in Q4 2023, selling an estimated $110K.
  • Forefront Analytics's ten largest holdings make up 54% of its $203M portfolio in Q4 2023.
  • Forefront Analytics opened 4 new positions and closed 4 in Q4 2023.
  • Forefront Analytics's portfolio value rose 15% quarter-over-quarter to $203M.

Based on Forefront Analytics's 13F filing for Q4 2023, filed 14 Feb 2024.